Differential killing of pre‐B acute lymphoblastic leukaemia cells by activated NK cells and the NK‐92 ci cell line

SUMMARY The use of NK cells in adoptive therapy for malignant disease is an area of great potential. Currently the only NK cell line in clinical trials is NK‐92, an activated NK cell line with a broad range of cytotoxicity against malignant cells. The activity of NK‐92 against pre‐B acute lymphoblas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental immunology 2002-08, Vol.129 (2), p.265-271
Hauptverfasser:	REID, G. S. D., BHARYA, S., KLINGEMANN, H.‐G., SCHULTZ, K. R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Apoptosis Applied cell therapy and gene therapy Basic Immunology Biological and medical sciences Cell Line Cytotoxicity, Immunologic Humans Immunotherapy, Adoptive In Vitro Techniques Interleukin-2 - pharmacology Killer Cells, Natural - immunology Medical sciences NK‐92 acute lymphoblastic leukaemia cytotoxicity PI‐3 kinase TNF Phosphatidylinositol 3-Kinases - metabolism Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - enzymology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Signal Transduction Transfusions. Complications. Transfusion reactions. Cell and gene therapy Tumor Cells, Cultured Tumor Necrosis Factor-alpha - metabolism Tumor Necrosis Factor-alpha - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!